No Data
No Data
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Raises Target Price to $11
Individual Investors Are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Biggest Owners and Were Hit After Market Cap Dropped US$26m
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Diamedica Therapeutics (DMAC)
DiaMedica Therapeutics Management to Meet Virtually With Lake Street
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
Unlock the Full List